^
    4d
    LP-168-CN201: A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=62, Active, not recruiting, Guangzhou Lupeng Pharmaceutical Company LTD. | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    rocbrutinib (LP-168)
    4d
    ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL (clinicaltrials.gov)
    P3, N=306, Not yet recruiting, Newave Pharmaceutical Inc
    New P3 trial
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2)
    |
    TP53 mutation
    |
    Jaypirca (pirtobrutinib) • rocbrutinib (LP-168)
    1m
    A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=150, Recruiting, Guangzhou Lupeng Pharmaceutical Company LTD. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • lenalidomide • bendamustine • rocbrutinib (LP-168)
    4ms
    A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=150, Not yet recruiting, Guangzhou Lupeng Pharmaceutical Company LTD.
    New P2 trial
    |
    Rituxan (rituximab) • lenalidomide • bendamustine • rocbrutinib (LP-168)
    10ms
    LP-168-CN301: Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=112, Recruiting, Guangzhou Lupeng Pharmaceutical Company LTD. | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • rocbrutinib (LP-168)
    11ms
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria. (clinicaltrials.gov)
    P1/2, N=150, Not yet recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    rocbrutinib (LP-168)
    1year
    A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=62, Active, not recruiting, Guangzhou Lupeng Pharmaceutical Company LTD. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    rocbrutinib (LP-168)
    over1year
    A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=62, Recruiting, Guangzhou Lupeng Pharmaceutical Company LTD. | Trial primary completion date: Feb 2024 --> Dec 2024
    Trial primary completion date
    |
    rocbrutinib (LP-168)
    over1year
    A Study of LP-168 in Participants with Relapse or Refractory B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=200, Recruiting, Guangzhou Lupeng Pharmaceutical Company LTD. | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    rocbrutinib (LP-168)
    almost2years
    LP-168-CN301: Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=112, Recruiting, Guangzhou Lupeng Pharmaceutical Company LTD. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • rocbrutinib (LP-168)
    almost2years
    The Mass Balance Study of LP-168 in Healthy Subjects (clinicaltrials.gov)
    P1, N=6, Completed, Guangzhou Lupeng Pharmaceutical Company LTD. | Active, not recruiting --> Completed
    Trial completion
    |
    rocbrutinib (LP-168)
    almost2years
    The Mass Balance Study of LP-168 in Healthy Subjects (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Guangzhou Lupeng Pharmaceutical Company LTD. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    rocbrutinib (LP-168)